Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications

被引:5
作者
Cardador, Camila Magalhaes [1 ]
Muehlmann, Luis Alexandre [2 ]
Coelho, Cintia Marques [3 ]
Silva, Luciano Paulino [4 ]
Garay, Aisel Valle [5 ]
Carvalho, Alexandra Maria dos Santos [6 ]
Bastos, Izabela Marques Dourado [6 ]
Longo, Joao Paulo Figueiro [1 ]
机构
[1] Univ Brasilia UnB, Inst Biol Sci, Dept Genet & Morphol, BR-70910900 Brasilia, DF, Brazil
[2] Univ Brasilia, Fac Ceilandia, BR-70910900 Brasilia, DF, Brazil
[3] Univ Brasilia UnB, Inst Biol Sci, Dept Genet & Morphol, Lab Synthet Biol, BR-70910900 Brasilia, DF, Brazil
[4] Embrapa Recursos Genet & Biotecnol, Lab Nanobiotecnol LNANO, BR-70770917 Brasilia, DF, Brazil
[5] Univ Brasilia UnB, Inst Biol Sci, Dept Cell Biol, Mol Biophys Lab, BR-70910900 Brasilia, DF, Brazil
[6] Univ Brasilia UnB, Dept Cell Biol, Pathogen Host Interface Lab, BR-70910900 Brasilia, DF, Brazil
关键词
liposome; nucleotide; protection; therapeutic; diagnostic; RIBOZYME-MEDIATED CLEAVAGE; MESSENGER-RNA; IN-VITRO; HAMMERHEAD RIBOZYMES; CATIONIC LIPOSOMES; DNA VACCINE; GENE-THERAPY; DELIVERY; INHIBITION; EXPRESSION;
D O I
10.3390/pharmaceutics15030873
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of nucleotides for biomedical applications is an old desire in the scientific community. As we will present here, there are references published over the past 40 years with this intended use. The main problem is that, as unstable molecules, nucleotides require some additional protection to extend their shelf life in the biological environment. Among the different nucleotide carriers, the nano-sized liposomes proved to be an effective strategic tool to overcome all these drawbacks related to the nucleotide high instability. Moreover, due to their low immunogenicity and easy preparation, the liposomes were selected as the main strategy for delivery of the mRNA developed for COVID-19 immunization. For sure this is the most important and relevant example of nucleotide application for human biomedical conditions. In addition, the use of mRNA vaccines for COVID-19 has increased interest in the application of this type of technology to other health conditions. For this review article, we will present some of these examples, especially focused on the use of liposomes to protect and deliver nucleotides for cancer therapy, immunostimulatory activities, enzymatic diagnostic applications, some examples for veterinarian use, and the treatment of neglected tropical disease.
引用
收藏
页数:25
相关论文
共 137 条
  • [1] Lipid-based nucleic acid therapeutics with in vivo efficacy
    Abu Sufian, Md.
    Ilies, Marc A.
    [J]. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2023, 15 (02)
  • [2] Vaccines platforms and COVID-19: what you need to know
    Acosta-Coley, Isabel
    Cervantes-Ceballos, Leonor
    Tejeda-Benitez, Lesly
    Sierra-Marquez, Lucellys
    Cabarcas-Montalvo, Maria
    Garcia-Espineira, Maria
    Coronell-Rodriguez, Wilfrido
    Arroyo-Salgado, Barbara
    [J]. TROPICAL DISEASES TRAVEL MEDICINE AND VACCINES, 2022, 8 (01)
  • [3] Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
    Adams, D.
    Gonzalez-Duarte, A.
    O'Riordan, W. D.
    Yang, C. -C.
    Ueda, M.
    Kristen, A. V.
    Tournev, I.
    Schmidt, H. H.
    Coelho, T.
    Berk, J. L.
    Lin, K. -P.
    Vita, G.
    Attarian, S.
    Plante-Bordeneuve, V.
    Mezei, M. M.
    Campistol, J. M.
    Buades, J.
    Brannagan, T. H., III
    Kim, B. J.
    Oh, J.
    Parman, Y.
    Sekijima, Y.
    Hawkins, P. N.
    Solomon, S. D.
    Polydefkis, M.
    Dyck, P. J.
    Gandhi, P. J.
    Goyal, S.
    Chen, J.
    Strahs, A. L.
    Nochur, S. V.
    Sweetser, M. T.
    Garg, P. P.
    Vaishnaw, A. K.
    Gollob, J. A.
    Suhr, O. B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 11 - 21
  • [4] The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
    Akinc, Akin
    Maier, Martin A.
    Manoharan, Muthiah
    Fitzgerald, Kevin
    Jayaraman, Muthusamy
    Barros, Scott
    Ansell, Steven
    Du, Xinyao
    Hope, Michael J.
    Madden, Thomas D.
    Mui, Barbara L.
    Semple, Sean C.
    Tam, Ying K.
    Ciufolini, Marco
    Witzigmann, Dominik
    Kulkarni, Jayesh A.
    van der Meel, Roy
    Cullis, Pieter R.
    [J]. NATURE NANOTECHNOLOGY, 2019, 14 (12) : 1084 - 1087
  • [5] Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
    Aleku, Manuela
    Schulz, Petra
    Keil, Oliver
    Santel, Ansgar
    Schaeper, Ute
    Dieckhoff, Britta
    Janke, Oliver
    Endruschat, Jens
    Durieux, Birgit
    Roeder, Nadine
    Loeffler, Kathrin
    Lange, Christian
    Fechtner, Melanie
    Moepert, Kristin
    Fisch, Gerald
    Dames, Sibylle
    Arnold, Wolfgang
    Jochims, Karin
    Giese, Klaus
    Wiedenmann, Bertram
    Scholz, Arne
    Kaufmann, Joerg
    [J]. CANCER RESEARCH, 2008, 68 (23) : 9788 - 9798
  • [6] The road to RNase P
    Altman, S
    [J]. NATURE STRUCTURAL BIOLOGY, 2000, 7 (10) : 827 - 828
  • [7] Prophylactic and therapeutic DNA vaccines against Chagas disease
    Arce-Fonseca, Minerva
    Rios-Castro, Martha
    del Carmen Carrillo-Sanchez, Silvia
    Martinez-Cruz, Mariana
    Rodriguez-Morales, Olivia
    [J]. PARASITES & VECTORS, 2015, 8
  • [8] BEIGELMAN L, 1995, NUCLEIC ACIDS RES, V23, P4434
  • [9] Neospora caninum truncated recombinant proteins formulated with liposomes and CpG-ODNs triggered a humoral immune response in cattle after immunisation and challenge
    Belen Novoa, Maria
    Sarli, Macarena
    Gabriela Reidel, Ivana
    Veaute, Carolina
    Valentini, Beatriz
    Evangelina Primo, Maria
    [J]. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2021, 238
  • [10] Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
    Berber, Burak
    Aydin, Cihan
    Kocabas, Fatih
    Guney-Esken, Gulen
    Yilancioglu, Kaan
    Karadag-Alpaslan, Medine
    Caliseki, Mehmet
    Yuce, Melek
    Demir, Sevda
    Tastan, Cihan
    [J]. GENE THERAPY, 2021, 28 (06) : 290 - 305